Modulation of p-glycoprotein transport function at the blood-brain barrier

Experimental Biology and Medicine

Volumn 230, Issue 2, 2005, Pages 118-127

  Bauer, Björn ^a   Hartz, Anika M S ^a,b   Fricker, Gert ^b   Miller, David S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ATP binding cassette; Central nervous system pharmacotherapy; Endothelin; Nuclear receptors; Regulation

Indexed keywords

ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREAST CANCER RESISTANCE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; CONCENTRATIVE NUCLEOSIDE TRANSPORTER; DIGOXIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; IVERMECTIN; METHOTREXATE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; OCTREOTIDE; OPIATE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PRAZOSIN; PROTEINASE INHIBITOR; RANITIDINE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN CAPILLARY; BRAIN INFECTION; CAPILLARY ENDOTHELIUM; CENTRAL NERVOUS SYSTEM; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG RESISTANCE; DRUG TRANSPORT; GENE EXPRESSION REGULATION; HUMAN; MEMBRANE PERMEABILITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; TRANSCRIPTION REGULATION;

BACTERIA (MICROORGANISMS);

EID: 12744253433     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020523000206     Document Type: Short Survey

References (78)

1. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. Plasma membrane localization of multidrug resistance-associated protein (MRP) homologues in brain capillary endothelial cells. J Pharmacol Exp Ther 311: 449-455, 2004.
2. Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 876:148-153, 2000.
3. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 990:95-112, 2003.
4. Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol 64:635-661, 2002.
5. Wijnholds J, deLange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105:279-285, 2000.
6. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264, 1999.
7. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57-66, 2002.
8. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398, 1999.
9. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610-617, 1996.
10. Hung LW, Wang IX, Nikaido K, Liu PQ, Ames GF, Kim SH. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature 396:703-707, 1998.
11. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423-429, 2004.
12. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007-1017, 2001.
13. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162, 1976.
14. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross reactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159-164, 1989.
15. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287, 1990.
16. Hsu SI, Cohen D, Kirschner LS, Lothstein L, Hartstein M, Horwitz SB. Structural analysis of the mouse mdrla (P-glycoprotein) promoter reveals the basis for differential transcript heterogeneity in multidrug-resistant 1774.2 cells. Mol Cell Biol 10:3596-3606, 1990.
17. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 9:3808-3820, 1989.
18. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM, Borst P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462, 1993.
19. van der Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 71:401-411, 1988.
20. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 12:101-109, 1998.
21. Romsicki Y, Sharom FJ. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 40:6937-6947, 2001.
22. Raggers RJ, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J 357:859-865, 2001.
23. Ernest S, Bello-Reuss E. Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol 10:2306-2313, 1999.
24. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25:1-6, 2000.
25. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 355:830-833, 1992.
26. Luker GD, Nilsson KR, Covey DF, Piwnica-Worms D. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J Biol Chem 274:6979-6991, 1999.
27. McRae MP, Brouwer KL, Kashuba AD. Cytokine regulation of P-glycoprotein. Drug Metab Rev 35:19-33, 2003.
28. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun Rev 3:188-192, 2004.
29. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 10:1295-1312, 2004.
30. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524, 1996.
31. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJM, Borst P. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502, 1994.
32. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727-733, 2001.
33. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397-410, 2003.
34. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 40:1269-1274, 2004.
35. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9:2849-2855, 2003.
36. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318, 2002.
37. Arnold SM, Patchell RA. Diagnosis and management of brain metastases. Hematol Oncol Clin North Am 15:1085-1107, vii, 2001.
38. Brandes AA, Basso U, Pasetto LM. Ermani M. New strategy developments in brain tumor therapy. Curr Pharm Des 7:1553-1580, 2001.
39. Nwaozuzu OM, Sellers LA, Barrand MA. Signalling pathways influencing basal and H(2)O(2)-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem 87:1043-1051, 2003.
40. Demeuse P, Fragner P, Leroy-Noury C, Mercier C, Payen L, Fardel O, Couraud PO, Roux F. Puromycin selectively increases mdrla expression in immortalized rat brain endothelial cell lines. J Neurochem 88:23-31, 2004.
41. Kipp H, Arias IM. Trafficking of canalicular ABC transporters in hepatocytes. Annu Rev Physiol 64:595-608, 2002.
42. Masereeuw R, Terlouw SA, van Aubel RA, Russel FG, Miller DS. Endothelin B receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol Pharmacol 57:59-67, 2000.
43. Terlouw SA, Masereeuw R, Russel FG, Miller DS. Nephrotoxicants induce endothelin release and signaling in renal proximal tubules: effect on drug efflux. Mol Pharmacol 59:1433-1440, 2001.
44. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of p-glycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 66:387-394, 2004.
45. Erdlenbruch B, Alipour M, Fricker G, Miller DS, Kugler W, Eibl H, Lakomek M. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol 140:1201-1210, 2003.
46. Miller G. Drug targeting. Breaking down barriers. Science 297:1116-1118, 2002.
47. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42:1083-1100, 1998.
48. Notenboom S, Miller DS, Smits P, Russel FG, Masereeuw R. Role of NO in endothelin-regulated drug transport in the renal proximal tubule. Am J Physiol Renal Physiol 282:F458-F464, 2002.
49. Miller DS, Sussman CR, Renfro JL. Protein kinase C regulation of p-glycoprotein-mediated xenobiotic secretion in renal proximal tubule. Am J Physiol 275:F785-F795, 1998.
50. Miller DS. Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants-a case of molecular hijacking. J Biochem Mol Toxicol 16:121-127, 2002.
51. Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, Baggetto LG. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP.130 protein. Nucleic Acids Res 32:3864-3876, 2004.
52. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64:943-948, 2002.
53. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587, 2001.
54. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann JM. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82, 1998.
55. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023, 1998.
56. Watkins RE, Noble SM, Redinbo MR. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel 5:150-158, 2002.
57. Schuetz E, Strom S. Promiscuous regulator of xenobiotic removal. Nat Med 7:536-537, 2001.
58. Dussault I, Forman BM. The nuclear receptor PXR: a master regulator of "homeland" defense. Crit Rev Eukaryot Gene Expr 12:53-64, 2002.
59. Rosenfeld JM, Vargas R Jr, Xie W, Evans RM. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 17:1268-1282, 2003.
60. Hartley DP, Dai X, He YD, Carlini EJ, Wang B, Huskey SE, Ulrich RG, Rushmore TH, Evers R, Evans DC. Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression. Mol Pharmacol 65:1159-1171, 2004.
61. Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 31:1296-1299, 2003.
62. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA, Moore JT. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27-39, 2000.
63. Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, Yan B. Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys 368:14-22, 1999.
64. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of p-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66:413-419, 2004.
65. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42:1501-1506, 2001.
66. Perloff MD, von Moltke LL, Greenblatt DJ. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica 34:133-150, 2004.
67. Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol Med 9:558-564, 2003.
68. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 32:20-27, 2004.
69. Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther 303:273-281, 2002.
70. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 3:268-280, 2000.
71. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J Biol Chem 278:8988-8995, 2003.
72. Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Down-regulation of mdrla expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 139:35-48, 2003.
73. Theron D, Barraud de Lagerie S, Tardivel S, Pelerin H, Demeuse P, Mercier C, Mabondzo A, Farinotti R, Lacour B, Roux F, Gimenez F. Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochem Pharmacol 66:579-587, 2003.
74. Tan KH, Purcell WM, Heales SJ, McLeod JD, Hurst RD. Evaluation of the role of P-glycoprotein in inflammation induced blood-brain barrier damage. Neuroreport 13:2593-2597, 2002.
75. Thevenod F. Nephrotoxicity and the proximal tubule. Insights from cadmium. Nephron Physiol 93:87-93, 2003.
76. Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 275:1887-1896, 2000.
77. Samoto K, Ikezaki K, Yokoyama N, Fukui M. P-glycoprotein expression in brain capillary endothelial cells after focal ischaemia in the rat. Neurol Res 16:217-223, 1994.
78. Felix RA, Barrand MA. P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem 80:64-72, 2002.